Biomarkers /
CD79A
Overview
CD79a molecule, immunoglobulin-associated alpha (CD79A) is a gene that encodes the Ig-alpha protein. The protein functions as a component of the B-cell antigen that is a member of the B lymphocyte antigen receptor multimeric protein complex. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
CD79A is altered in 0.86% of all cancers with colon adenocarcinoma, lung adenocarcinoma, cutaneous melanoma, endometrial endometrioid adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in CD79A are CD79A Mutation (0.37%), CD79A Loss (0.21%), CD79A Amplification (0.19%), CD79A X190_splice (0.03%), and CD79A V69I (0.02%) [3].
Clinical Trials
Significance of CD79A in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.